Nature Research Round Table: Organoids as an Enabling Technology for Precision Cancer Medicine

Dr. Mathew Garnett describes his work banking tumor organoids to create new disease models for cancer that more accurately reflect the disease. Dr. Garnett is a Group Leader at the Wellcome Sanger Institute

This presentation was part of a Round Table series titled “Advances in Organoid Applications”, organized in partnership with Nature Research and held at the Springer Nature headquarters in London, UK in June 2019. There, global organoid experts gathered to discuss the current state of the technology. Core discussions centered around protocol standardization, translation into patient care, nomenclature, and understanding what questions a given organoid culture can and can’t answer.

Dr. Mathew Garnett describes his work banking tumor organoids to create new disease models for cancer that more accurately reflect the disease. Dr. Garnett is a Group Leader at the Wellcome Sanger Institute This presentation was part of a Round Table series titled “Advances in Organoid Applications”, organized in partnership with Nature Research and held at the Springer Nature headquarters in London, UK in June 2019. There, global organoid experts gathered to discuss the current state of the technology. Core discussions centered around protocol standardization, translation into patient care, nomenclature, and understanding what questions a given organoid culture can and can’t answer. Get the full picture by reading a commentary and watching webinars and interviews featuring the Nature Research Round Table presenters.
Publish Date: February 27, 2020